REFERENCES
2. Chinnery PF. Mitochondrial disorders overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle; 1993.
3. McCormick EM, Zolkipli-Cunningham Z, Falk MJ. Mitochondrial disease genetics update: recent insights into the molecular diagnosis and expanding phenotype of primary mitochondrial disease. Curr Opin Pediatr 2018;30:714-24.
4. Thompson K, Collier JJ, Glasgow RIC, Robertson FM, Pyle A, et al. Recent advances in understanding the molecular genetic basis of mitochondrial disease. J Inherit Metab Dis 2020;43:36-50.
5. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 2015;77:753-9.
6. Vandebona H, Mitchell P, Manwaring N, Griffiths K, Gopinath B, et al. Prevalence of mitochondrial 1555A-->G mutation in adults of European descent. N Engl J Med 2009;360:642-4.
7. Manwaring N, Wang JJ, Mitchell P, Sue CM. Mitochondrial DNA disease prevalence: still underrecognized? Ann Neurol 2008;64:471. author reply 471-2
8. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7:230-3.
11. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, et al. Mitochondrial diseases. Nat Rev Dis Primers 2016;2:16080.
12. Munnich A, Rötig A, Chretien D, Cormier V, Bourgeron T, et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996;19:521-7.
13. Liang C, Ahmad K, Sue CM. The broadening spectrum of mitochondrial disease: shifts in the diagnostic paradigm. Biochim Biophys Acta 2014;1840:1360-7.
14. Grier J, Hirano M, Karaa A, Shepard E, Thompson JLP. Diagnostic odyssey of patients with mitochondrial disease: results of a survey. Neurol Genet 2018;4:e230.
15. Theunissen TEJ, Nguyen M, Kamps R, Hendrickx AT, Sallevelt S, et al. Whole exome sequencing is the preferred strategy to identify the genetic defect in patients with a probable or possible mitochondrial cause. Front Genet 2018;9:400.
16. Ohtake A, Murayama K, Mori M, Harashima H, Yamazaki T, et al. Diagnosis and molecular basis of mitochondrial respiratory chain disorders: exome sequencing for disease gene identification. Biochimi Biophys Acta 2014;1840:1355-9.
17. Pronicka E, Piekutowska-Abramczuk D, Ciara E, Trubicka J, Rokicki D, et al. New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre. J Transl Med 2016;14:174.
18. Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, et al. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA 2014;312:68-77.
19. Wortmann SB, Koolen DA, Smeitink JA, van den Heuvel L, Rodenburg RJ. Whole exome sequencing of suspected mitochondrial patients in clinical practice. J Inherit Metab Dis 2015;38:437-43.
20. Puusepp S, Reinson K, Pajusalu S, Murumets Ü, Õiglane-Shlik E, et al. Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia. Mol Genet Metab Rep 2018;15:80-9.
21. Kohda M, Tokuzawa Y, Kishita Y, Nyuzuki H, Moriyama Y, et al. A comprehensive genomic analysis reveals the genetic landscape of mitochondrial respiratory chain complex deficiencies. PLoS Genet 2016;12:e1005679.
22. Schoonen M, Smuts I, Louw R, Elson JL, van Dyk E, et al. Panel-based nuclear and mitochondrial next-generation sequencing outcomes of an ethnically diverse pediatric patient cohort with mitochondrial disease. J Mol Diagn 2019;21:503-13.
23. Legati A, Reyes A, Nasca A, Invernizzi F, Lamantea E, et al. New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies. Biochim Biophys Acta 2016;1857:1326-35.
24. Meienberg J, Bruggmann R, Oexle K, Matyas G. Clinical sequencing: is WGS the better WES? Hum Genet 2016;135:359-62.
25. Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci U S A 2015;112:5473-8.
26. Puttick C, Kumar KR, Davis RL, Pinese M, Thomas DM, et al. A highly sensitive mitochondrial variant analysis pipeline for whole genome sequencing data. bioRxiv 2019:852210.
27. Ernster L, Ikkos D, Luft R. Enzymic activities of human skeletal muscle mitochondria: a tool in clinical metabolic research. Nature 1959;184:1851-4.
28. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962;41:1776-804.
29. Engel WK, Cunningham GG. Rapid examination of muscle tissue. an improved trichrome method for fresh-frozen biopsy sections. Neurology 1963;13:919-23.
30. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984;16:481-8.
31. Fukuhara N, Tokiguchi S, Shirakawa K, Tsubaki T. Myoclonus epilepsy associated with ragged-red fibres (mitochondrial abnormalities): disease entity or a syndrome? Light-and electron-microscopic studies of two cases and review of literature. J Neurol Sci 1980;47:117-33.
32. Schon EA, Hirano M, DiMauro S. Mitochondrial encephalomyopathies: clinical and molecular analysis. J Bioenerg Biomembr 1994;26:291-9.
33. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, et al. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002;59:1406-11.
34. Naviaux RK. Developing a systematic approach to the diagnosis and classification of mitochondrial disease. Mitochondrion 2004;4:351-61.
35. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992;2:125-35.
36. DiMauro S, Garone C. Historical perspective on mitochondrial medicine. Dev Disabil Res Rev 2010;16:106-13.
37. Koenig MK. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol 2008;38:305-13.
38. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, et al. Sequence and organization of the human mitochondrial genome. Nature 1981;290:457-65.
39. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988;242:1427-30.
40. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717-9.
41. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651-3.
42. McCormick E, Place E, Falk MJ. Molecular genetic testing for mitochondrial disease: from one generation to the next. Neurotherapeutics 2013;10:251-61.
43. Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res 2016;44:D1251-7.
44. Frazier AE, Thorburn DR, Compton AG. Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. J Biol Chem 2019;294:5386-95.
45. Craven L, Alston CL, Taylor RW, Turnbull DM. Recent advances in mitochondrial disease. Annu Rev Genomics Hum Genet 2017;18:257-75.
47. Zeviani M, Bresolin N, Gellera C, Bordoni A, Pannacci M, et al. Nucleus-driven multiple large-scale deletions of the human mitochondrial genome: a new autosomal dominant disease. Am J Hum Genet 1990;47:904-14.
48. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995;11:144-9.
49. Goto Y. Clinical features of MELAS and mitochondrial DNA mutations. Muscle Nerve Suppl 1995;3:S107-12.
50. Chin J, Marotta R, Chiotis M, Allan EH, Collins SJ. Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective. Mitochondrion 2014;17:34-41.
51. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. J Neurol Neurosurg Psychiatry 2013;84:936-8.
52. Lake NJ, Compton AG, Rahman S, Thorburn DR. Leigh syndrome: one disorder, more than 75 monogenic causes. Ann Neurol 2016;79:190-203.
53. Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, et al. A Post-Hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat 2013;34:1721-6.
54. Wortmann SB, Mayr JA, Nuoffer JM, Prokisch H, Sperl W. A guideline for the diagnosis of pediatric mitochondrial disease: the value of muscle and skin biopsies in the genetics era. Neuropediatrics 2017;48:309-14.
55. Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019;45:661-73.
56. Niyazov DM, Kahler SG, Frye RE. Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment. Mol Syndromol 2016;7:122-37.
57. Raymond FL, Horvath R, Chinnery PF. First-line genomic diagnosis of mitochondrial disorders. Nat Rev Genet 2018;19:399-400.
58. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015;17:689-701.
59. Sue CM, Quigley A, Katsabanis S, Kapsa R, Crimmins DS, et al. Detection of MELAS A3243G point mutation in muscle, blood and hair follicles. J Neurol Sci 1998;161:36-9.
60. Broomfield A, Sweeney MG, Woodward CE, Fratter C, Morris AM, et al. Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease. J Inherit Metab Dis 2015;38:445-57.
61. DaRe JT, Vasta V, Penn J, Tran NTB, Hahn SH. Targeted exome sequencing for mitochondrial disorders reveals high genetic heterogeneity. BMC Med Genet 2013;14:118.
62. Rodenburg RJ, Schoonderwoerd GC, Tiranti V, Taylor RW, Rötig A, et al. A multi-center comparison of diagnostic methods for the biochemical evaluation of suspected mitochondrial disorders. Mitochondrion 2013;13:36-43.
64. Gellerich FN, Mayr JA, Reuter S, Sperl W, Zierz S. The problem of interlab variation in methods for mitochondrial disease diagnosis: enzymatic measurement of respiratory chain complexes. Mitochondrion 2004;4:427-39.
65. Medja F, Allouche S, Frachon P, Jardel C, Malgat M, et al. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. Mitochondrion 2009;9:331-9.
66. Dimmock DP, Lawlor MW. Presentation and diagnostic evaluation of mitochondrial disease. Pediatr Clin North Am 2017;64:161-71.
68. Suomalainen A. Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011;34:277-82.
69. Oglesbee D, Freedenberg D, Kramer KA, Anderson BD, Hahn SH. Normal muscle respiratory chain enzymes can complicate mitochondrial disease diagnosis. Pediatr Neurol 2006;35:289-92.
70. Stenton SL, Prokisch H. Advancing genomic approaches to the molecular diagnosis of mitochondrial disease. Essays biochem 2018;62:399-408.
71. Vasta V, Merritt JL 2nd, Saneto RP, Hahn SH. Next-generation sequencing for mitochondrial diseases: a wide diagnostic spectrum. Pediatr Int 2012;54:585-601.
72. Plutino M, Chaussenot A, Rouzier C, Ait-El-Mkadem S, Fragaki K, et al. Targeted next generation sequencing with an extended gene panel does not impact variant detection in mitochondrial diseases. BMC Med Genet 2018;19:57.
73. Lieber DS, Calvo SE, Shanahan K, Slate NG, Liu S, et al. Targeted exome sequencing of suspected mitochondrial disorders. Neurology 2013;80:1762-70.
74. Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 2012;4:118ra10.
75. Wagner M, Berutti R, Lorenz-Depiereux B, Graf E, Eckstein G, et al. Mitochondrial DNA mutation analysis from exome sequencing - A more holistic approach in diagnostics of suspected mitochondrial disease. J Inherit Metab Dis 2019;42:909-17.
76. Falk MJ, Pierce EA, Consugar M, Xie MH, Guadalupe M, et al. Mitochondrial disease genetic diagnostics: optimized whole-exome analysis for all MitoCarta nuclear genes and the mitochondrial genome. Discov Med 2012;14:389-99.
77. Abicht A, Scharf F, Kleinle S, Schön U, Holinski-Feder E, et al. Mitochondrial and nuclear disease panel (Mito-aND-Panel): combined sequencing of mitochondrial and nuclear DNA by a cost-effective and sensitive NGS-based method. Mol Genet Genomic Med 2018;6:1188-98.
78. Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. The genetics and pathology of mitochondrial disease. J Pathol 2017;241:236-50.
79. Murayama K, Shimura M, Liu Z, Okazaki Y, Ohtake A. Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases. J Hum Genet 2019;64:113-25.
80. Stark Z, Tan TY, Chong B, Brett GR, Yap P, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genet Med 2016;18:1090-6.
81. Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
82. McCormick EM, Muraresku CC, Falk MJ. Mitochondrial genomics: a complex field now coming of age. Curr Genet Med Rep 2018;6:52-61.
83. Khan S, Ince-Dunn G, Suomalainen A, Elo LL. Integrative omics approaches provide biological and clinical insights: examples from mitochondrial diseases. J Clin Invest 2020;130:20-8.
84. Mascalchi M, Montomoli M, Guerrini R. Neuroimaging in mitochondrial disorders. Essays Biochem 2018;62:409-21.
85. Gropman AL. Neuroimaging in mitochondrial disorders. Neurotherapeutics: the journal of the American Society for Experimental. NeuroTherapeutics 2013;10:273-85.
86. Saneto RP, Friedman SD, Shaw DWW. Neuroimaging of mitochondrial disease. Mitochondrion 2008;8:396-413.
87. Ahmad K, Tan K, Sue C. The neuro-ophthalmology of mitochondrial disease with a particular focus on the morphology of the optic nerve head. J Clin Neurosci 2014;21:2043.
88. Finsterer J, Frank M. Gastrointestinal manifestations of mitochondrial disorders: a systematic review. Therap Adv Gastroenterol 2017;10:142-54.
89. Rahman S, Poulton J, Marchington D, Suomalainen A. Decrease of 3243 A-->G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am J Hum Genet 2001;68:238-40.
90. Boenzi S, Diodato D. Biomarkers for mitochondrial energy metabolism diseases. Essays Biochem 2018;62:443-54.
91. Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, et al. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 2013;81:1819-26.
92. Suomalainen A. Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. Expert Opin Med Diagn 2013;7:313-7.
93. Lehtonen JM, Forsström S, Bottani E, Viscomi C, Baris OR, et al. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. Neurology 2016;87:2290-9.
94. Forsström S, Jackson CB, Carroll CJ, Kuronen M, Pirinen E, et al. Fibroblast growth factor 21 drives dynamics of local and systemic stress responses in mitochondrial myopathy with mtDNA deletions. Cell Metab 2019;30:1040-54.e7.
95. Kalko SG, Paco S, Jou C, Rodríguez MA, Meznaric M, et al. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 2014;15:91.
96. Davis RL, Liang C, Sue CM. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology 2016;86:2010-5.
97. Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 2015;78:814-23.
98. Ji X, Zhao L, Ji K, Zhao Y, Li W, et al. Growth differentiation factor 15 Is a novel diagnostic biomarker of mitochondrial diseases. Mol Neurobiol 2017;54:8110-6.
99. Montero R, Yubero D, Villarroya J, Henares D, Jou C, et al. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS One 2016;11:e0148709.
100. Poulsen NS, Madsen KL, Hornsyld TM, Eisum AV, Fornander F, et al. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion 2020;50:35-41.
101. Tsygankova PG, Itkis YS, Krylova TD, Kurkina MV, Bychkov IO, et al. Plasma FGF-21 and GDF-15 are elevated in different inherited metabolic diseases and are not diagnostic for mitochondrial disorders. J Inherit Metab Dis 2019;42:918-33.
102. Picardi E, Pesole G. Mitochondrial genomes gleaned from human whole-exome sequencing. Nat Methods 2012;9:523-4.
103. Ross MG, Russ C, Costello M, Hollinger A, Lennon NJ, et al. Characterizing and measuring bias in sequence data. Genome Biol 2013;14:R51.
104. Posey JE. Genome sequencing and implications for rare disorders. Orphanet J Rare Dis 2019;14:153.
105. Barbitoff YA, Polev DE, Glotov AS, Serebryakova EA, Shcherbakova IV, et al. Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage. Sci Rep 2020;10:2057.
